Publications by authors named "Takaaki Fujimura"

Claim this Profile
C
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer.
Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori

Mol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer.
Takaaki Fujimura, Koh Furugaki, Hayato Mizuta, Satoshi Muraoka, Makoto Nishio

NPJ Precis Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes.
Koh Furugaki, Takaaki Fujimura, Hayato Mizuta, Takuya Yoshimoto, Takashi Asakawa

NPJ Precis Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies.
Natsumi Kawasaki, Yoriko Yamashita-Kashima, Takaaki Fujimura, Shigeki Yoshiura, Naoki Harada

Mol Biol Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.
Yoriko Yamashita-Kashima, Keigo Yorozu, Takaaki Fujimura, Natsumi Kawasaki, Mitsue Kurasawa

Int J Hematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yoriko Yamashita-Kashima, Sei Shu, Masahiro Osada, Takaaki Fujimura, Shigeki Yoshiura

Cancer Chemother Pharmacol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.
Takaaki Fujimura, Yoriko Yamashita-Kashima, Natsumi Kawasaki, Shigeki Yoshiura, Naoki Harada

Mol Cancer Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homeostasis of the ER redox state subsequent to proteasome inhibition.
Yuki Oku, Masahiro Kariya, Takaaki Fujimura, Jun Hoseki, Yasuyoshi Sakai

Sci Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
Yoriko Yamashita-Kashima, Sei Shu, Masahiro Osada, Takaaki Fujimura, Shigeki Yoshiura

Cancer Chemother Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against -fusion-positive non-small cell lung cancer cells.
Takaaki Fujimura, Koh Furugaki, Naoki Harada, Yasushi Yoshimura

Cancer Biol Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
Yoriko Yamashita-Kashima, Yasushi Yoshimura, Takaaki Fujimura, Sei Shu, Mieko Yanagisawa

Cancer Chemother Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a stable ERroGFP variant suitable for monitoring redox dynamics in the ER.
Jun Hoseki, Asami Oishi, Takaaki Fujimura, Yasuyoshi Sakai

Biosci Rep· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis